Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic
patients with subclinical nephropathy.
Author(s): Ninomiya Y, Arakawa M.
Affiliation(s): Department of Medicine (II), Niigata University, School of Medicine, Japan.
Publication date & source: 1989, Diabetes Res. , 10(3):129-34
To determine whether the urinary albumin excretion rate (UAER) could be reduced
without adversely affecting renal function, prostaglandin E1 (PGE1) was
administrated to Type 2 (non-insulin-dependent) diabetic patients with both high
and low microalbuminuria, who were matched for age, weight, height and hemoglobin
A1c levels. The study was performed as a randomized double-blind trial, with the
patients receiving either PGE1 or placebo. In patients who initially had a UAER
above 30 mug/min (high UAER group), the UAER was significantly (p less than 0.01)
reduced by the administration of PGE1. In this group the UAER after stopping PGE1
administration was comparable to baseline values. During PGE1 administration in
the high UAER group, the filtration fraction (FF) was significantly reduced (p
less than 0.01) while the glomerular filtration rate (GFR) was unchanged. In
patients with an initial UAER below 30 mug/min (low UAER group) the UAER was not
altered during the administration of PGE1. In this low UAER group both the FF and
GFR remained unchanged. The urinary beta2-microglobulin excretion rate did not
change significantly during the administration of PGE1 in either group. These
results suggest that the decreased UAER in patients with an abnormally high
albumin excretion, may be due to a change in the glomerular permeability to
albumin related to a decreased FF.
|